empasiprubart

Empasiprubart (formerly ARGX-117) is a first-in-class, humanized monoclonal antibody developed by argenx that targets complement component C2, a key protein at the intersection of the classical and lectin pathways of the complement cascade[1][4][5]. By binding to C2 in a pH- and calcium-dependent manner, empasiprubart inhibits activation of these pathways while leaving the alternative pathway intact, potentially reducing tissue damage and organ dysfunction associated with autoimmune diseases[1][4][6]. The antibody is engineered with NHANCE mutations to enhance recycling via FcRn, allowing for prolonged circulation and efficient removal of C2 from serum[1]. Empasiprubart is being investigated for several severe autoimmune indications including multifocal motor neuropathy (MMN), dermatomyositis (DM), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and delayed graft function after kidney transplantation[3][5][8].